Intellia Therapeutics, Inc.
NTLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14 | $14 | $17 | $13 |
| % Growth | -3.3% | -14.3% | 29.2% | – |
| Cost of Goods Sold | $79 | $0 | $0 | $0 |
| Gross Profit | -$65 | $14 | $17 | $13 |
| % Margin | -472.8% | 100% | 100% | 100% |
| R&D Expenses | $95 | $97 | $108 | $117 |
| G&A Expenses | $31 | $27 | $29 | $32 |
| SG&A Expenses | $46 | $27 | $29 | $32 |
| Sales & Mktg Exp. | $16 | $0 | $0 | $0 |
| Other Operating Expenses | -$95 | $0 | $0 | $0 |
| Operating Expenses | $46 | $124 | $137 | $149 |
| Operating Income | -$111 | -$110 | -$121 | -$136 |
| % Margin | -808.9% | -772.2% | -726.6% | -1,059.9% |
| Other Income/Exp. Net | $10 | $9 | $6 | $8 |
| Pre-Tax Income | -$101 | -$101 | -$114 | -$129 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$101 | -$101 | -$114 | -$129 |
| % Margin | -735.2% | -710.8% | -687.6% | -1,001.2% |
| EPS | -0.92 | -0.98 | -1.1 | -1.27 |
| % Growth | 6.1% | 10.9% | 13.4% | – |
| EPS Diluted | -0.92 | -0.98 | -1.1 | -1.27 |
| Weighted Avg Shares Out | 110 | 104 | 104 | 102 |
| Weighted Avg Shares Out Dil | 110 | 104 | 104 | 102 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $9 | $11 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $2 | $2 | $3 |
| EBITDA | -$96 | -$108 | -$118 | -$134 |
| % Margin | -699.4% | -754.8% | -711.5% | -1,039.9% |